References: [1] Huang T, Zhang K, Sun L, Xue X, Zhang C, Shu Z, Mu N, Gu J, Zhang W, Wang Y, Zhang Y, Zhang W
An earlier Phase II trial11 and two essentially identical Phase III trials (a study of at least moderate size that compares a new treatment with the current standard of care in patients), Gout 1 and Gout 2 have been presented.13 Data on shrinkage of tophi with this agent was also presented in 6/09.13 Cardiac events have occurred during the studies of Krystexxa, and the FDA reviewed them closely and concluded that they did not appear due to the medication
The rationale is that NAD levels decline with age, affecting cellular energy production
It is a synthetic peptide derived from a protective protein sequence found in gastric juice
Typical Daily Dose: Most research protocols use a dose between 250mcg and 500mcg per day
Nature 379 , 6972 (1991)